Aurelio Cafaro

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.

Editorial: HIV-1 Tat, an enhancer of virus infectivity and disease promoter: target for preventive and therapeutic interventions.

Journal: Frontiers in immunology
Published: May 14, 2026

Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up study.

Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up study.

Journal: Frontiers in immunology
Published: December 16, 2025

Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Journal: International journal of molecular sciences
Published: December 30, 2023

HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine.

HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine.

Journal: Expert review of vaccines
Published: June 13, 2022

Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.

Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.

Journal: EBioMedicine
Published: January 14, 2021

New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.

New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.

Journal: Archives of virology
Published: January 14, 2021

HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication.

HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication.

Journal: International journal of molecular sciences
Published: November 19, 2020

The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation.

The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation.

Journal: Vaccines
Published: April 28, 2020

HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.

HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy.

Journal: Expert review of vaccines
Published: January 21, 2020

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Journal: Vaccines
Published: July 16, 2019

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study.

Journal: Frontiers in immunology
Published: October 31, 2018

The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells.

The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells.

Journal: AIDS (London, England)
Published: December 28, 2017
Showing 1-12 of 33

Last Updated: 09/26/2026